Abstract: TH-PO0500
Early Initiation of Targeted-Release Budesonide in IgAN with Low Baseline Proteinuria: A Real-World Analysis of Kidney Function Changes
Session Information
- Glomerular Diseases: Clinical, Outcomes, and Therapeutics Research - IgAN
October 22, 2026 | Location: Exhibit Hall A, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Glomerular Diseases
- 1402 Glomerular Diseases: Clinical, Outcomes, and Therapeutics
Authors
- Meng, Qingmei, The Affiliated Central Hospital of Dalian University of Technology, Dalian, China
- Liu, Cong, School of Pharmacy, South-Central University for Nationalities, Wuhan, China
- Wu, Yulin, The Affiliated Central Hospital of Dalian University of Technology, Dalian, China
- Liu, Hong, The Affiliated Central Hospital of Dalian University of Technology, Dalian, China
- Liu, Shuxin, The Affiliated Central Hospital of Dalian University of Technology, Dalian, China
Background
Based on the efficacy and safety demonstrated by targeted-release budesonide in multiple clinical trials of IgA nephropathy (IgAN), this study evaluated changes in renal parameters before and after targeted-release budesonide in low baseline proteinuria population.
Methods
This single-center retrospective study included IgAN patients with relatively low baseline proteinuria（Over 75% had 24h-Upro < 1.0 g） who received targeted-release budesonide (16 mg daily) for 9 months between May 2024 and March 2026. Serum and urine samples were collected at baseline and at 9 months. Primary renal parameters included 24-hour proteinuria (24h-Upro) and eGFR, alongside serum creatinine (SCR), urinary red blood cells (URBC), and cystatin C (CysC).
Results
Among the 20 patients, 11 (55.0%) were male, with a median age of 48 years (range 36-65) and a median 24h-Upro of 501.0 mg/24 h (range 80.0-1661.0). After 9 months of targeted-release budesonide, significant improvement was observed in most renal parameters. Median 24h-Upro decreased by 59.1%, from 501.0 (range 80.0-1661.0) to 176.5 (range 31.0-819.0) mg/24 h (p < 0.0001), while median eGFR increased by 10.2%, from 51.3 (range 38.4-97.9) to 59.3 (range 40.3-95.0) mL/min/1.73 m^2 (p = 0.03). Median URBC also decreased significantly, by 82.8%, respectively, from 11.2 (range 0.1-126.3) to 2.3 (range 0.3-7.1) cells/HPF (p = 0.00017). (Figure 1). The treatment was generally well tolerated.
Conclusion
This real-world study showed that targeted-release budesonide was associated with improved renal function and reduced renal injury in IgAN with low baseline proteinuria, supporting its clinical benefit.
Funding
- Clinical Revenue Support